the aid library

LIST OPTIONS

Filter

6667

Plaidoyer pour la santé mentale, le handicap et les droits humains : guide d’orientation QualityRights de l’OMS

Organisation Mondiale de la Santé OMS (2019) C_WHO

Les modules de formation et d’orientation QualityRights ont été élaborés pour renforcer les connaissances, les compétences et la compréhension des principales parties prenantes sur la manière de promouvoir les droits des personnes en situation de handicap psychosocial, intellectuel ou cogni... more

Plans individualisés de rétablissement et outil d’auto-support : outil d’auto-support QualityRights de l’OMS

Organisation Mondiale de la Santé OMS (2021) C_WHO

Policy brief: mainstreaming quality of care in empanelled hospitals under AB PM-JAY

World Health Organisation (WHO) (2022) C_WHO

This report presents key findings from a study carried out on the ‘Mainstreaming quality of care in empanelled hospitals under PMJAY’. It provides a detailed analysis of current coverage and perceptions of quality accreditation and certification across PMJAY empanelled hospitals from three diffe... more

Rétablissement et droit à la santé : formation de base QualityRights de l’OMS : services sociaux et de santé mentale : guide de formation

Organisation Mondiale de la Santé OMS (2022) C_WHO

Soutien à la prise de décision et directives anticipées en psychiatrie : formation spécialisée QualityRights de l’OMS : guide de formation

Organisation Mondiale de la Santé OMS (2022) C_WHO

Soutien individuel par et pour les personnes ayant un savoir expérientiel en santé mentale : guide d’orientation QualityRights de l’OMS

Organisation Mondiale de la Santé OMS (2022) C_WHO

Download (102)

View PDF (125)

Supported decision-making and advance planning: WHO QualityRights Specialized training: course guide

w (2022) C_WHO

Mental health, disability and human rights: WHO QualityRights core training - for all services and all people: course guide

World Health Organization WHO (2022) C_WHO

External Link

Melarsoprol Resistance in African Trypanosomiasis

Fairlamb, A.H.; Horn, D. Elsevier Ltd. (2018) CC

Arsenical monotherapies were previously very successful for treating human African trypanosomiasis (HAT). Melarsoprol resistance emerged as early as the 1970s and was widespread by the late 1990s. Melarsoprol resistance represents the only example of widespread drug resistance in HAT patients wher... more

External Link

Business models for sustainable development: Projects of global extension of medical technologies of Japan

Nozaki, I.; Y. Sugiura; N. Fujita et al. Global Health & Medicine (2021) C1

Japan has been implementing projects of global extension of medical technologies under an official development assistance policy to improve public health and medicine by promoting Japanese medical technologies worldwide. The current work examines the impact and goals of implementing this new scheme.... more

Download (117)

View PDF (123)

Reclaim the Gains - The Case for Investing in the Global Financing Facility 2021–2025

Global Financing Facility (GFF) Global Financing Facility (GFF) (2021) CC

The GFF needs an additional US$2.5 billion from 2021 to 2025 to enable countries to protect health gains and accelerate progress toward the 2030 Goals. Of this amount, the GFF urgently needs to secure new pledges of US$1.2 billion by the end of 2021 to help its current 36 partner countries protect ... more

Download (286)

View PDF (384)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (201)

View PDF (202)

Guidance on development and implementation of a national deployment and vaccination plan for vaccines against pandemic influenza and other respiratory viruses of pandemic potential

World Health Organization WHO (2023) C_WHO

Vaccines are powerful weapons in the fight against pandemic viruses as shown by responses to both the 2009 H1N1 influenza and the COVID-19 pandemics. However, planning for accessing, allocating and deploying vaccines in a pandemic situation is a complex endeavour, beset with multiple challenges at a... more

Global Strategy for Asthma Management and Prevention (2022 update)

Global Initiative for Asthma (2022) CC2

The reader acknowledges that this report is intended as an evidence-based asthma management strategy, for the use of health professionals and policy-makers. It is based, to the best of our knowledge, on current best evidence and medical knowledge and practice at the date of publication. When assessi... more

Global Strategy for Asthma Management and Prevention (2019 update)

Global Initiative for Asthma (2019) CC2

Guidance Note: Mental health and Psychosocial Support Implications of Mpox Outbreaks, September 2024
recommended

International Federation of Red Cross and Red Crescent Societies (2024) CC

The IFRC Psychosocial Centre has published a guidance note providing an overview of the psychosocial consequences of virus outbreaks, with a focus on mpox, and outlines key considerations for MHPSS programming. The current mpox outbreaks present numerous challenges for responding National Societi... more

Comprehensive Hospital Preparedness Checklist for Coronavirus Disease 2019 (COVID-19)

Centers for Disease Control and Prevention CDC (2020) C_CDC

The following checklist can help hospitals assess and improve their preparedness for responding to a community-wide outbreak of COVID-19. Each hospital will need to adapt this checklist to meet its unique needs and circumstances. This checklist should be used as one of several tools for evaluating c... more

COVID-19 rapid guideline: antibiotics for pneumonia in adults in hospital

NICE guideline (2020) C2

This guideline is for: • health and care practitioners • health and care staff involved in planning and delivering services • commissioners. The recommendations bring together: • existing national and international guidance and policies • advice from specialists working in the NHS fr... more

Technical and Regulatory Aspects of the Extended Use, Reuse, and Reprocessing of Respirators during Shortages
recommended

Pan American Health Organization PAHO (2020) C_WHO

N95 or equivalent respirators are single-use personal protective equipment (PPE) designed for use by health workers that provide direct care to patients with diseases transmitted by aerosols or during aerosol generating procedures (AGP) for patients with acute respiratory disease, as is the case of ... more

IN FOCUS - Testing is not enough!

Action against AIDS Germany (2020) C1

What measures can we take to overcome the corona crisis, limit its consequences or use scarce resources efficiently? Every day we experience uncertainties and contradictions on these questions among scientists, health experts, politicians and in society. We must all strive for a broad consensus to o... more

Guidance Note: Mental health and Psychosocial Support Implications of Mpox Outbreaks, September 2024 recommended

Technical and Regulatory Aspects of the Extended Use, Reuse, and Reprocessing of Respirators during Shortages recommended

Guidance Note: Mental health and Psychosocial Support Implications of Mpox Outbreaks, September 2024
recommended

Technical and Regulatory Aspects of the Extended Use, Reuse, and Reprocessing of Respirators during Shortages
recommended